Home › Funds › Equitable › EQ/T. Rowe Price Health Sciences Portfolio
Fund family: Equitable · Filed by EQ ADVISORS TRUST (CIK 1027263) · SEC series S000062644
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,345 with, 27 against, 0 abstentions (not counted as with management). Shareholder proposals: 1 FOR, 25 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Equitable’s manager page (393,894 ballot items across 72 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Equitable | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 92.4% | 1,280 | 92.5% | 339,726 |
| Backed environmental and social shareholder proposals at US companies | n/a | 8 | 9.6% | 3,486 |
Each ballot item this fund voted is set against the votes of the other Equitable funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Equitable funds on 55 items (5.2% of the 1,061 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Equitable funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| AbbVie Inc. | 2026-05-08 | Election of Class II Directors: Frederick H. Waddell | Against | FOR — 21 of 21 Equitable funds | Against | Passed (calculated), 93.7% support |
| AbbVie Inc. | 2026-05-08 | Election of Class II Directors: Jennifer L. Davis | Against | FOR — 21 of 21 Equitable funds | Against | Passed (calculated), 93.1% support |
| AbbVie Inc. | 2026-05-08 | Election of Class II Directors: Melody B. Meyer | Against | FOR — 21 of 21 Equitable funds | Against | Passed (calculated), 98.3% support |
| Waters Corporation | 2026-01-27 | To approve the adjournment of the Special Meeting, if necessary, (a) to solicit additional proxies in the event there are not sufficient votes at the time of the Special Meeting to approve the Share Issuance Proposal, (b) if there are insufficient shares of Waters Common Stock represented (either in | Against | FOR — 22 of 22 Equitable funds | Against | — |
| IQVIA Holdings Inc. | 2026-04-23 | Approve the adoption of the IQVIA Holdings Inc. 2026 Incentive and Stock Award Plan. | Against | FOR — 20 of 21 Equitable funds | Against | Approved, 65.5% support |
| Denali Therapeutics Inc. | 2026-06-03 | ELECTION OF DIRECTORS: Jennifer Cook | For | WITHHOLD — 9 of 9 Equitable funds | For | Elected, 60.9% support |
| Chugai Pharmaceutical Co., Ltd. | 2026-03-26 | Elect Director Okuda, Osamu | Against | FOR — 9 of 9 Equitable funds | Against | — |
| Mirum Pharmaceuticals, Inc. | 2026-06-15 | To elect the Board's three Class III nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Timothy Walbert | For | WITHHOLD — 8 of 8 Equitable funds | For | Elected, 69.7% support |
| Scholar Rock Holding Corporation | 2026-06-04 | To elect four Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal: Kristina Burow | For | WITHHOLD — 8 of 8 Equitable funds | For | Elected, 81.6% support |
| Scholar Rock Holding Corporation | 2026-06-04 | To elect four Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal: Michael Gilman | For | WITHHOLD — 8 of 8 Equitable funds | For | Elected, 78.2% support |
| Xenon Pharmaceuticals Inc. | 2026-06-02 | To approve the Corporation's 2026 Equity Incentive Plan; | Against | FOR — 8 of 8 Equitable funds | Against | Approved, 68.0% support |
| Palvella Therapeutics, Inc. | 2026-06-10 | Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 5. | Against | FOR — 8 of 8 Equitable funds | Against | Passed (calculated), 75.2% support |
| Stoke Therapeutics, Inc. | 2026-06-03 | Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Adrian Krainer, Ph.D. | For | WITHHOLD — 8 of 8 Equitable funds | For | Passed (calculated), 73.0% support |
| Ionis Pharmaceuticals, Inc. | 2026-06-04 | Election of Directors: Joan E. Herman | Against | FOR — 7 of 7 Equitable funds | Against | Passed (calculated), 96.4% support |
| Corvus Pharmaceuticals, Inc. | 2026-06-11 | To elect two Class I Directors with terms to expire at the 2029 annual meeting of stockholders: Linda S. Grais, M.D. J.D. | For | WITHHOLD — 7 of 7 Equitable funds | For | Passed (calculated), 87.2% support |
| Wave Life Sciences Ltd. | 2025-08-05 | The election of the nominees for director: Christian Henry | For | AGAINST — 7 of 7 Equitable funds | For | Passed (calculated), 85.4% support |
| Rocket Pharmaceuticals, Inc. | 2026-05-20 | The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Peter Fong, Ph.D. | Withhold | FOR — 7 of 7 Equitable funds | Against | Passed (calculated), 98.1% support |
| Apogee Therapeutics, Inc. | 2026-06-09 | Election of Class III Directors for terms expiring in 2029: William (BJ) Jones, Jr. | For | WITHHOLD — 7 of 7 Equitable funds | For | Passed (calculated), 81.5% support |
| MBX Biosciences, Inc. | 2026-06-04 | Election of two Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified, or until their earlier death, resignation or removal: Edward T. Mathers | For | WITHHOLD — 6 of 6 Equitable funds | For | Passed (calculated), 80.8% support |
| Agios Pharmaceuticals, Inc. | 2026-06-18 | To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Cynthia Smith | For | WITHHOLD — 6 of 6 Equitable funds | For | Passed (calculated), 68.3% support |
| Alumis Inc. | 2026-06-30 | To elect the three Class II director nominees named below to serve until the Company's 2029 annual meeting of stockholders: Zhengbin (Bing) Yao, Ph.D. | For | WITHHOLD — 6 of 6 Equitable funds | For | Passed (calculated), 84.1% support |
| Evommune, Inc. | 2026-06-02 | To elect two nominees for Class I directors, each to hold office until the 2029 Annual Meeting of Stockholders: Luis Pena | Withhold | FOR — 6 of 6 Equitable funds | Against | — |
| Iovance Biotherapeutics, Inc. | 2026-06-10 | To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 6. | Against | FOR — 5 of 5 Equitable funds | Against | — |
| Caris Life Sciences, Inc. | 2026-06-04 | Election of Directors: Peter M. Castleman | For | WITHHOLD — 8 of 9 Equitable funds | For | Elected, 76.3% support |
| Moderna, Inc. | 2026-05-06 | To elect two Class II director nominees set forth in the proxy statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her other respective successor is duly elected and qualified or such director's earlier death, resignation or removal: Sa | For | AGAINST — 13 of 17 Equitable funds | For | Elected, 81.0% support |
| Company | Meeting | Item | This fund | Most Equitable funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | 2026-04-30 | Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal No. 5 and/or Proposal No. 6. | Against | FOR — 4 of 4 Equitable funds | Against | Approved, 94.4% support |
| Boston Scientific Corporation | 2026-04-30 | Shareholder Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting." | Against | FOR — 14 of 20 Equitable funds | For | Not approved, 42.8% support |
| Thermo Fisher Scientific Inc. | 2026-05-20 | An advisory vote to approve named executive officer compensation. | For | AGAINST — 11 of 16 Equitable funds | For | Not approved, 31.8% support |
| UroGen Pharma Ltd. | 2025-08-26 | To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Arie Belldegrun, M.D. | For | WITHHOLD — 5 of 6 Equitable funds | For | Elected, 91.0% support |
| Celcuity Inc. | 2026-05-14 | Elect eight directors: Polly A. Murphy | Withhold | FOR — 5 of 7 Equitable funds | Against | Passed (calculated), 91.1% support |
| Celcuity Inc. | 2026-05-14 | Elect eight directors: Richard E. Buller | Withhold | FOR — 5 of 7 Equitable funds | Against | Passed (calculated), 90.3% support |
| Repligen Corporation | 2026-05-14 | Election of Directors: Glenn P. Muir | For | AGAINST — 7 of 11 Equitable funds | For | Elected, 74.4% support |
| Caris Life Sciences, Inc. | 2026-06-04 | Election of Directors: Danny Phillips | For | WITHHOLD — 6 of 9 Equitable funds | For | Elected, 81.8% support |
| Caris Life Sciences, Inc. | 2026-06-04 | Election of Directors: Laura I. Johansen | For | WITHHOLD — 6 of 9 Equitable funds | For | Elected, 86.5% support |
| Rhythm Pharmaceuticals, Inc. | 2026-06-24 | Election of the Class III directors, each to serve for a three year term until the 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: David W.J. McGirr | For | WITHHOLD — 5 of 8 Equitable funds | For | Passed (calculated), 85.9% support |
| Iovance Biotherapeutics, Inc. | 2026-06-10 | To approve, by non-binding advisory vote, the compensation of our named executive officers; | Against | FOR — 3 of 4 Equitable funds | Against | — |
| Celcuity Inc. | 2026-05-14 | To approve the Celcuity Inc. Amended and Restated Employee Stock Purchase Plan. | For | AGAINST — 4 of 6 Equitable funds | For | — |
| Inspire Medical Systems, Inc. | 2026-04-30 | Approval of an amendment and restatement of the Inspire Medical Systems, Inc. 2018 Incentive Award Plan. | Against | FOR — 3 of 4 Equitable funds | Against | Approved, 62.0% support |
| Ultragenyx Pharmaceutical Inc. | 2026-05-14 | Nominees: Daniel G. Welch | For | WITHHOLD — 3 of 4 Equitable funds | For | Passed (calculated), 90.1% support |
| Ultragenyx Pharmaceutical Inc. | 2026-05-14 | Nominees: Shehnaaz Suliman, M.D. | For | WITHHOLD — 3 of 4 Equitable funds | For | Passed (calculated), 89.4% support |
| Rocket Pharmaceuticals, Inc. | 2026-05-20 | The approval of the proposed stock option exchange program; and | Against | FOR — 4 of 6 Equitable funds | Against | Approved, 72.1% support |
| Rocket Pharmaceuticals, Inc. | 2026-05-20 | The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: David P. Southwell | Withhold | FOR — 4 of 6 Equitable funds | Against | Passed (calculated), 68.2% support |
| Kestra Medical Technologies, Ltd. | 2025-09-03 | The approval of the Kestra Medical Technologies, Ltd. 2025 Employee Stock Purchase Plan. | For | AGAINST — 4 of 6 Equitable funds | For | — |
| Cytokinetics, Incorporated | 2026-05-27 | 3 wordings Election of Class I Directors for terms expiring in 2029: Edward M. Kaye, M.D. | Withhold | FOR — 5 of 9 Equitable funds | Against | Passed (calculated), 97.0% support |
| Roivant Sciences Ltd. | 2025-09-10 | To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Keith Manchester | For | WITHHOLD — 4 of 7 Equitable funds | For | Elected, 70.6% support |
| Roivant Sciences Ltd. | 2025-09-10 | To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Melissa Epperly | For | WITHHOLD — 4 of 7 Equitable funds | For | Elected, 73.5% support |
| Guardant Health, Inc. | 2026-06-17 | Election of Class II Directors: Ian Clark | For | WITHHOLD — 4 of 7 Equitable funds | For | Elected, 65.0% support |
| Guardant Health, Inc. | 2026-06-17 | Election of Class II Directors: Manuel Hidalgo Medina | For | WITHHOLD — 4 of 7 Equitable funds | For | Elected, 75.5% support |
| BioMarin Pharmaceutical Inc. | 2026-06-02 | Election of Directors: Ian T. Clark | For | AGAINST — 4 of 7 Equitable funds | For | Elected, 88.3% support |
| Mirum Pharmaceuticals, Inc. | 2026-06-15 | To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Lon Cardon, Ph.D., FMedSci | For | WITHHOLD — 4 of 7 Equitable funds | For | Elected, 85.3% support |
| Mirum Pharmaceuticals, Inc. | 2026-06-15 | To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: William Fairey | For | WITHHOLD — 4 of 7 Equitable funds | For | Elected, 86.8% support |
| Alignment Healthcare, Inc. | 2026-06-04 | Election of Directors: David Hodgson | Withhold | FOR — 3 of 5 Equitable funds | Against | Elected, 60.8% support |
| Alignment Healthcare, Inc. | 2026-06-04 | Election of Directors: Jacqueline Kosecoff | Withhold | FOR — 3 of 5 Equitable funds | Against | Elected, 76.1% support |
| Alignment Healthcare, Inc. | 2026-06-04 | Election of Directors: Jody Bilney | Withhold | FOR — 3 of 5 Equitable funds | Against | Elected, 76.1% support |
| Summit Therapeutics Inc. | 2026-06-10 | ELECTION OF DIRECTORS: Mostafa Ronaghi | For | WITHHOLD — 2 of 3 Equitable funds | For | Passed (calculated), 99.9% support |
Download all 55 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 77.5% of this fund’s 1,372 such votes could be given a sector; the other 309 (22.5%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 997 | 23 | 2.3% |
| Industrials | 49 | 2 | 4.1% |
| Consumer Staples | 17 | 1 | 5.9% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 807 | 0 |
| Audit-related | 159 | 0 |
| Say-on-Pay | 140 | 0 |
| Compensation | 107 | 2 |
| Capital Structure | 84 | 0 |
| Corporate Governance | 74 | 16 |
| Other Social Issues | 7 | 5 |
| Shareholder Rights and Defenses | 7 | 1 |
| Extraordinary Transactions | 4 | 0 |
| Environment or Climate | 3 | 3 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $28M | 10 | 2 |
| Thermo Fisher Scientific Inc. | May 20, 2026 | $9M | 13 | 0 |
| argenx SE | November 18, 2025 | $9M | 1 | 0 |
| UnitedHealth Group Incorporated | June 1, 2026 | $8M | 12 | 1 |
| Merck & Co., Inc. | May 26, 2026 | $7M | 18 | 3 |
| AbbVie Inc. | May 8, 2026 | $6M | 8 | 1 |
| argenx SE | May 6, 2026 | $6M | 12 | 0 |
| Intuitive Surgical, Inc. | April 30, 2026 | $6M | 13 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| June 1, 2026 | UnitedHealth Group Incorporated | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | Against | For |
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| May 14, 2026 | CVS Health Corporation | Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposal | Against | For |
| May 13, 2026 | Elevance Health, Inc. | Shareholder Proposal Requesting an Independent Study on the Impact of Prohibiting Corporate Contributions to Partisan 527 Tax-Exempt Political Groups. Shareholder proposal | Against | For |
1,392 ballot items at 160 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, EQ/T. Rowe Price Health Sciences Portfolio voted at 160 shareholder meetings of 156 companies, on 1,392 ballot items in all. Where management made a recommendation, the fund followed it on 98.0% of the items and voted against it 27 times. Its most frequent area of disagreement was corporate governance (16 of its votes against management). It voted on 26 shareholder proposals. It voted FOR the board's own proposals about as often as Equitable's funds as a whole (92.4% against 92.5%). It voted differently from most Equitable funds on 55 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Equitable’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.